Pollen Biotechnology of Crop Plants Group, Margarita Salas Center of Biological Research, CIB-CSIC, Ramiro de Maeztu 9, 28040, Madrid, Spain.
Pollen Biotechnology of Crop Plants Group, Margarita Salas Center of Biological Research, CIB-CSIC, Ramiro de Maeztu 9, 28040, Madrid, Spain; Plant Reproduction and Development Laboratory, ENS de Lyon, CNRS, INRAE, UCBL, F-69342, Lyon, France.
J Plant Physiol. 2024 Dec;303:154334. doi: 10.1016/j.jplph.2024.154334. Epub 2024 Aug 23.
In vitro plant embryogenesis and microcallus formation are systems which are required for plant regeneration, a process during which cell reprogramming and proliferation are critical. These systems offer many advantages in breeding programmes, such as doubled-haploid production, clonal propagation of selected genotypes, and recovery of successfully gene-edited or transformed plants. However, the low proportion of reprogrammed cells in many plant species makes these processes highly inefficient. Here we report a new strategy to improve in vitro plant cell reprogramming using small molecule inhibitors of mammalian leucine rich repeat kinase 2 (LRRK2), which are used in pharmaceutical applications for cell reprogramming, but never used in plants before. LRRK2 inhibitors increased in vitro embryo production in three different systems and species, microspore embryogenesis of oilseed rape and barley, and somatic embryogenesis in cork oak. These inhibitors also promoted plant cell reprogramming and proliferation in Arabidopsis protoplast cultures. The benzothiazole derivative JZ1.24, a representative compound of the tested molecules, modified the expression of the brassinosteroid (BR)-related genes BIN2, CPD, and BAS1, correlating with an activation of BR signaling. Additionally, the LRRK2 inhibitor JZ1.24 induced the expression of the embryogenesis marker gene SERK1-like. The results suggest that the use of small molecules from the pharmaceutical field could be extended to promote in vitro reprogramming of plant cells towards embryogenesis or microcallus formation in a wider range of plant species and in vitro systems. This technological innovation would help to develop new strategies to improve the efficiency of in vitro plant regeneration, a major bottleneck in plant breeding.
体外植物胚胎发生和微愈伤组织形成是植物再生所必需的系统,在这个过程中,细胞重编程和增殖至关重要。这些系统在育种计划中具有许多优势,例如产生双倍体、选择基因型的无性繁殖,以及成功编辑或转化的植物的恢复。然而,许多植物物种中重编程细胞的比例很低,使得这些过程效率非常低。在这里,我们报告了一种使用哺乳动物亮氨酸重复激酶 2 (LRRK2) 的小分子抑制剂来改善体外植物细胞重编程的新策略,这些抑制剂用于细胞重编程的药物应用,但以前从未在植物中使用过。LRRK2 抑制剂增加了三个不同系统和物种的体外胚胎产量,油菜和大麦的小孢子胚胎发生,以及软木橡木的体细胞胚胎发生。这些抑制剂还促进了拟南芥原生质体培养中的植物细胞重编程和增殖。苯并噻唑衍生物 JZ1.24 是测试分子的代表性化合物,它修饰了油菜素甾体(BR)相关基因 BIN2、CPD 和 BAS1 的表达,与 BR 信号的激活相关。此外,LRRK2 抑制剂 JZ1.24 诱导了胚胎发生标记基因 SERK1-like 的表达。结果表明,来自制药领域的小分子的使用可以扩展到促进更广泛的植物物种和体外系统中植物细胞向胚胎发生或微愈伤组织形成的体外重编程。这项技术创新将有助于开发新的策略来提高体外植物再生的效率,这是植物育种的主要瓶颈。